Financhill
Back

PTC Therapeutics Quote, Financials, Valuation and Earnings

PTC Therapeutics Price Quote

$50.29

PTC Therapeutics Key Stats

Buy
51
PTC Therapeutics (PTCT) is a Buy

Day range:
$49.28 - $54.16
52-week range:
$23.58 - $54.16
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
4.27
P/B ratio:
0%

Volume:
1.5M
Avg. volume:
877.6K
1-year change:
109.63%
Market cap:
$3.9B
Revenue:
$937.8M
EPS:
$-5.94

How Much Does PTC Therapeutics Make?

Is PTC Therapeutics Growing As A Company?

  • What Is PTC Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0%
  • What Is PTC Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

PTC Therapeutics Stock Price Performance

  • Did PTC Therapeutics Stock Go Up Last Month?
    PTC Therapeutics share price went up by 24.26% last month
  • Did PTCT's Share Price Rise Over The Last Year?
    PTCT share price rose by 109.63% over the past 1 year

What Is PTC Therapeutics 52-Week High & Low?

PTC Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy PTC Therapeutics?

  • How Much Debt Does PTC Therapeutics Have?
    Total long term debt quarterly is $285.1M
  • How Much Cash Does PTC Therapeutics Have?
    Cash and short term investments quarterly total is $1B
  • What Is PTC Therapeutics’s Book Value Per Share?
    Book value per share is -13.70

Is PTC Therapeutics Cash Flow Positive?

  • What Is PTCT Cash Flow From Operations?
    Cash flow from operations (TTM) is -$178M
  • What Is PTC Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $849.9M
  • What Is PTC Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$317.9M

PTC Therapeutics Return On Invested Capital

Data Unavailable

PTC Therapeutics Earnings Date & Stock Price

PTC Therapeutics Competitors

  • Who Are PTC Therapeutics's Competitors?
    Below is a list of companies who compete with PTC Therapeutics or are related in some way:
    • Alnylam Pharmaceuticals Inc (ALNY)
    • BridgeBio Pharma Inc (BBIO)
    • ClearPoint Neuro Inc (CLPT)
    • Pfizer Inc (PFE)
    • Vertex Pharmaceuticals Inc (VRTX)

PTC Therapeutics Dividend Yield

PTC Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 17.76%
Revenue: 0.11% 14.54%

Analyst Recommendations

Buy Recommendations: 6
Hold Recommendations: 5
Sell Recommendations: 1
Price Target: 55.00
Upside from Last Price: 9.37%

Major Shareholders

  • How many PTCT shares are owned by institutional investors?
    124.8M PTCT shares are owned by institutional investors
  • How many PTCT shares are owned by insiders?
    1.3M PTCT shares are owned by insiders